This paper presents a comprehensive survey on anti-drone systems. After drones were released for non-military usages, drone incidents in the unarmed population are gradually increasing. However, it is unaffordable to construct a military grade anti-drone system for every private or public facility due to installation and operation costs, and regulatory restrictions. We focus on analyzing antidrone system that does not use military weapons, investigating a wide range of anti-drone technologies, and deriving proper system models for reliable drone defense. We categorized anti-drone technologies into detection, identification, and neutralization, and reviewed numerous studies on each. Then, we propose a hypothetical anti-drone system that presents the guidelines for adaptable and effective drone defense operations. Further, we discuss drone-side safety and security schemes that could nullify current anti-drone methods, and propose future solutions to resolve these challenges.

Recently, unmanned aerial vehicles (UAVs) have been applied to various applications. In order to perform repetitive and accurate tasks with a UAV, it is more efficient for the operator to perform the tasks through an integrated management program rather than controlling the UAVs one by one through a controller. In this environment, control packets must be reliably delivered to the UAV to perform missions stably. However, wireless communication is at risk of packet loss or packet delay. Typical network communications can respond to situations in which packets are lost by retransmitting lost packets. However, in the case of UAV control, delay due to retransmission is fatal, so control packet loss and delay should not occur. As UAVs move quickly, there is a high risk of accidents if control packets are lost or delayed. In order to stably control a UAV by transmitting control messages, we propose a control packet transmission scheme, ConClone. ConClone replicates control packets and then transmits them over multiple network connections to increase the probability of successful control packet transmission. We implemented ConClone using real equipment, and we verified its performance through experiments and theoretical analysis.

Background Central blood pressure and central pulse pressure have a better correlation with the risk of cardiovascular disease compared to those of peripheral measurement. In a previous study, a second-generation beta-blocker showed poor CBP-lowering effects. However, the effect on CBP by third-generation beta-blockers is not fully elucidated. Thus, this randomised study investigated whether nebivolol-based hypertension treatment may confer advantages over telmisartan, an angiotensin II receptor-blocker, in reducing CBP. Methods This was a prospective, randomised, multicentre, open-label, controlled trial that evaluated 98 hypertensive patients. Patients received either nebivolol- (N=49) or telmisartan-based (N=49) treatment for hypertension for 12 weeks with a target BP of ≤140/80. The primary outcome was the difference in change from baseline central systolic BP (cSBP) after 12 weeks. Results There were no significant differences between the two groups in baseline central and peripheral SBP. The mean change in cSBP from baseline (ΔcSBP) was −17.2±3 mmHg for nebivolol group (P<0.001) and −29.9±3 mmHg for telmisartan group (P<0.001). The difference in ΔcSBP between the two groups was significant (12.7mmHg, 95% confidence interval [CI], 4.13 to 21.2; P=0.004). Peripheral SBP (pSBP) decreased less in nebivolol group compared to telmisartan group (−18.0±3 in nebivolol group vs. −26.3±3 in telmisartan group, P=0.032). After adjusting for reduction in pSBP, reduction in cSBP was higher in telmisartan group compared to nebivolol group, as shown by the ratio of changes in cSBP and pSBP (ΔcSBP/ΔpSBP; 0.67 for nebivolol group vs. 1.11 for telmisartan group, P=0.080), albeit without statistical significance. Conclusions Nebivolol-based hypertension treatment may have less potent CBP-lowering effects compared to telmisartan. However, larger-scale studies are warranted to further elaborate our findings. Funding Acknowledgement Type of funding sources: None.

No abstract

Background Elderly patients undergoing percutaneous coronary intervention (PCI) generally have a high risk of adverse clinical outcomes. We investigated the long-term clinical impact of PCI on coronary bifurcation disease in elderly patients in Korea and Italy. Methods From the BIFURCAT (comBined Insights from the Unified RAIN and COBIS bifurcAtion regisTries) data, we evaluated 5,537 patients who underwent PCI for coronary bifurcation disease. The primary outcome was major adverse cardiac events (MACEs), defined as the composite of target vessel myocardial infarction, target lesion revascularisation, and stent thrombosis. Kaplan–Meier estimates and Cox proportional hazard models were used to compare elderly patients (aged ≥75 years) and younger patients (aged <75 years). Results A total of 1,415 patients (26%) were aged ≥75 years. Elderly patients were more frequently female, had higher rates of hypertension and chronic kidney disease (CKD), and presented more frequently with left main (LM) disease. After a median follow-up of 2.1 years, MACEs were comparable between elderly and younger patients. In multivariable analysis, old age was not an independent predictor of MACEs (p=0.977). In elderly patients, CKD and LM disease were independent predictors of MACEs, whereas in younger patients, hypertension, diabetes, CKD, reduced left ventricular ejection fraction, LM disease, and two-stent strategy usage were independent predictors. Conclusions Elderly patients who underwent coronary bifurcation PCI with second-generation drug-eluting stents demonstrated similar clinical outcomes to those of younger patients. Both CKD and LM disease were independent predictors of MACEs, regardless of age after coronary bifurcation PCI. Funding Acknowledgement Type of funding sources: None.